Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Ceclor, Cefastac; Belgium: Doccefaclo; Bulgaria: Cefaclor, Medoclor; Cyprus: Ceclor, Medoclor, Remeclor, Syntoclor; Czech Republic: Vercef; Finland: Kefolor; France: Alfatil, Cefaclor, Haxifal; Germany: Ceclorbeta, Cef-Diolan, Cefaclor, Infectocef, Panoral, Sigacefal Forte; Greece: Cefaclor; Hungary: Ceclor, Cecloretta; Ireland: Cefaclor, Cefager, Distaclor, Keftid, Pinaclor; Italy: Altaclor, Bacticef, Bactigram, Cefaclor, Cefacloro, Clorazer, Geniclor, Kliacef, Macovan, Necloral, Oralcef, Panacef, Performer, Selviclor, Takecef, Tibifor, Valeclor OS Sosp.; Malta: Ceclor, Eurocefix, Performer; Netherlands: Ceclor, Cefaclor; Poland: Ceclor, CEK, Kloracef, Panclor, Serviclor, Vercef; Portugal: Ceclor, Cefaclor; Romania: Ceclodyne, Ceclor, Ceclozone, Cefaclor, Cefaklor, Cloracef, Medoclor, Vercef; Slovakia: Vercef; Slovenia: Ceclor, Cefaklor; Spain: Ceclor, Cefaclor; UK: Distaclor.

North America

Canada: Ceclor, Cefaclor; USA: Cefaclor, Raniclor.

Latin America

Brazil: Ceclor, Cefaclor, Cefacloren, Clorcin-Ped; Mexico: Arcefal, Ceclor, Cefaclor, Cefalan, Ceflacid, Fasiclor, Fermed, Ranclor, Serviclor, Tecnoclor.


Japan: Alenfral, CCL, Ceclodan, Cefaclor, Ericanal, Kefpolin, Kefral, Kulilel, L-Kefral, Ruberal, Tokiclor.

Drug combinations


Cefaclor: C~15~H~14~ClN~3~O~4~S H~2~O. Mw: 385.82. (1) 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(aminophenylacetyl)amino]-3-chloro-8-oxo-, monohydrate, [6R-[6α,7β(R*)]]-; (2)(6R,7R)-7-[(R)-2-Amino-2-phenylacetamido]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate; (3) 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid monohydrate. CAS-70356-03-5; CAS-53994-73-3 (anhydrous). (1976).

Pharmacologic Category

Antibacterials; Second Generation Cephalosporins. (ATC-Code: J01DC04).

Mechanism of action

Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins. Less active against Gram-negative bacteria than some other second generation cephalosporins. Inactive against fungi and viruses. Active in vitro and in clinical infections against Gram-positive aerobic bacteria such as staphylococci (including coagulase-positive, coagulase-negative, and penicillinase producing strains), Streptococcus pneumoniae, and S. pyogenes (group A β-hemolytic streptococci). Enterococci (e.g. Enterococcus faecalis) and oxacillin-resistant (methicillin-resistant) staphylococci are resistant. Active in vitro and in clinical infections against Gram-negative aerobic bacteria such as H. influenzae (except β-lactamase-negative, ampicillin-resistant (BLNAR) strains), Moraxella catarrhalis (including β-lactamase-producing strains), Escherichia coli, Klebsiella, and Proteus mirabilis, H. parainfluenzae, Citrobacter diversus, and Neisseria gonorrhoeae. Inactive against Acinetobacter, Enterobacter, Morganella morganii, Proteus vulgaris, Providencia, Pseudomonas, and Serratia. Active in vitro against anaerobic bacteria such as Bacteroides (excluding B. fragilis), Peptococcus niger, Peptostreptococcus, and Propionibacterium acnes.

Therapeutic use

Susceptible bacterial infections including otitis media, lower respiratory tract infections, acute exacerbations of chronic bronchitis, pharyngitis and tonsillitis, urinary tract infections, skin and skin structure infections, bone and joint infections.

Pregnancy and lactiation implications

Adverse events not observed in animal reproduction studies. It is not known if cefaclor crosses the placenta; other cephalosporins cross the placenta and are considered safe for use during pregnancy. An increased risk of teratogenic effects has not been observed following maternal use of cefaclor.

Unlabeled use


Hypersensitivity to cefaclor, any component of the formulation, or other cephalosporins.

Warnings and precautions

Use with caution in history of penicillin allergy, especially IgE-mediated reactions (e.g. anaphylaxis, angioedema, urticaria). Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea and pseudomembranous colitis. BLNAR strains of H. influenzae should be considered resistant to cefaclor. Use with caution in renal impairment. Extended release tablets are not approved for use in children <16 years of age. Some products may contain phenylalanine. Positive direct Coombs’, false-positive urinary glucose test using cupric sulfate, false-positive serum or urine creatinine with Jaffé reaction.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart